Results 101 to 110 of about 4,941,729 (331)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

On Sharp Interface Limits for Diffuse Interface Models for Two-Phase Flows [PDF]

open access: yes, 2012
We discuss the sharp interface limit of a diffuse interface model for a two-phase flow of two partly miscible viscous Newtonian fluids of different densities, when a certain parameter \epsilon>0 related to the interface thickness tends to zero.
Abels, Helmut, Lengeler, Daniel
core  

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Exactly Integrable Dynamics of Interface between Ideal Fluid and Light Viscous Fluid

open access: yes, 2004
It is shown that dynamics of the interface between ideal fluid and light viscous fluid is exactly integrable in the approximation of small surface slopes for two-dimensional flow.
Ablowitz   +22 more
core   +1 more source

Amphiphilic nanoparticles generate curvature in lipid membranes and shape liposome–liposome interfaces

open access: hybrid, 2021
Enrico Lavagna   +5 more
openalex   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Electron effective mass determination across a β-(Al0.2Ga0.8)2O3//β-Ga2O3 interface by Kramers-Kronig analysis [PDF]

open access: bronze, 2021
Adrian Chmielewski   +4 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Operando Raman spectroscopy uncovers hydroxide and CO species enhance ethanol selectivity during pulsed CO2 electroreduction

open access: yesNature Communications
Pulsed CO2 electroreduction (CO2RR) has recently emerged as a facile way to in situ tune the product selectivity, in particular toward ethanol, without re-designing the catalytic system.
Antonia Herzog   +6 more
doaj   +1 more source

Valley interference effects on a donor electron close to a Si/SiO2 interface

open access: yes, 2007
We analyze the effects of valley interference on the quantum control and manipulation of an electron bound to a donor close to a Si/SiO2 interface as a function of the valley-orbit coupling at the interface. We find that, for finite valley-orbit coupling,
Calderon, M. J.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy